Stock Alert for Antigenics Inc. (Delaware)(AGEN) " />

Stock Alert for Antigenics Inc. ($AGEN)

Antigenics Inc. (Delaware) (NASDAQ: $AGEN)

Antigenics Inc. (AGEN) is a biotechnology company developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Oncophage has been tested in Phase III clinical trials for the treatment of renal cell carcinoma, a common type of kidney cancer, and for the treatment of metastatic melanoma. It has also been tested in Phase I and Phase II clinical trials in a range of indications and is in Phase II clinical trials in glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant (QS-21), which is used in numerous vaccines in third-party clinical trials as advanced as Phase III for a variety of diseases; AG-707, a therapeutic vaccine program tested in a Phase I clinical trial for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic tested in a Phase I clinical trial for the treatment of solid malignancies and B-cell lymphomas.

The Company was formerly known as Antigenics L.L.C. and changed its name to Antigenics Inc. in February 2000. Antigenics Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Share Statistics (12-May-10) FY






Q4 2008 Q4 2009 %


Symbol AGEN Revenue, $Mn 5.55M 2.65M 52.3% 0.52M 0.55M 5.8%
Current price $1.29 Gross marg. 100.0% 100.0% 0.0% 100.0% 100.0% 0.0%
52wk Range: $3.34-0.51 Oper. margin -599.3% -1472% 138.1% -1321% -945.5% 28.4%
Avg Vol (3m): 1,872,860 Net margin -683.6% -1162% 70.0% 782.7% 338.2% 57.0%
Market Cap. 117.32M
Dil. Shares Outst. 94.2M EPS, $ -0.81 -0.47 42.0% 0.07 0.02 71.4%

Source:, SEC Filings.

Financial Summary

The Company reported a net loss attributable to common stockholders of $9.0 million, or $0.10 per share, basic and diluted, for the first quarter of 2010, compared with a net loss attributable to common stockholders in the first quarter of 2009 of $9.7 million, or $0.14 per share, basic and diluted. The Company’s net cash burn (cash used in operating activities plus capital expenditures and dividend payments) for the first quarter of 2010 and 2009 respectively was $6.1 million and $9.8 million. The 2010 net cash burn figure primarily reflects the Company’s efforts to support Oncophage as well as cost containment. Cash, cash equivalents and short-term investments amounted to $23.9 million as of March 31, 2010.

Subsequent to the end of the quarter, the Company exchanged approximately 954,000 shares of common stock for approximately $2.3 million in face value of its 5.25% convertible notes. The original balance of this note was $50 million, of which approximately $17.7 million remains outstanding after a series of exchanges and repurchases.

As of April 26, 2010, the Company regained compliance with the continued listing requirements of the NASDAQ Capital Markets, and the matter is now closed.

Financial Strength (12-May-2010) Company Industry Sector S&P 500
Quick Ratio (MRQ) n/a n/a n/a n/a
Current Ratio (MRQ) n/a n/a n/a n/a
Long-Term Debt to Equity (MRQ) n/a n/a n/a n/a
Total Debt to Equity (MRQ) n/a n/a n/a n/a

Source:, SEC Filings.

Analyst Consensus

Buy Outperform Hold Underperform Sell No Opinion

This is the consensus forecast amongst one polled investment analysts. Against the Antigenics Inc (Delaware) company.

Analyst Detail Buy Outperform Hold Underperform Sell No Opinion
Latest 0 0 1 0 0 0
4 weeks ago 0 0 1 0 0 0
2 months ago 0 0 1 0 0 0
3 months ago 0 0 1 0 0 0
Last year 0 0 1 0 0 0


No consensus analysis data available.


Investment Highlights

The Company recently announced that Dr. Andrew Parsa of the Brain Tumor Research Center at the University of California, San Francisco (UCSF) will present clinical data from a Phase II trial testing Oncophage in the treatment of recurrent glioma at the International Conference on Brain Tumor Research and Therapy on May 20, 2010. He also presented on the subject of vaccine therapy for glioma at the American Association of Neurological Surgeons conference in Philadelphia May 4, 2010.

Two Phase 2 clinical trials testing Oncophage in glioma, or brain cancer, are currently underway. One trial is being conducted in patients with recurrent disease and the other in patients with newly diagnosed disease. Both trials are being led by Dr. Parsa. The trials are sponsored by the National Institutes of Health in conjunction with patient advocacy groups and will evaluate overall survival, progression-free survival and immune response.

AGEN is currently assessing potential registrational strategies for Oncophage in the treatment of glioma in the U.S. and other territories.

The first patient in Russia with intermediate-risk renal cell carcinoma (RCC), or kidney cancer, has received treatment with Oncophage commercial product. While there appears to be a limited private pay market in Russia, AGEN continues to explore local distribution channels to support broader commercialization efforts as well as government reimbursement.

Over the past month, AGEN held meetings with regulatory agencies from select European member states to assist in determining whether there is a viable path forward for resubmission of the Oncophage marketing authorization application for intermediate-risk RCC in Europe. The Company plans to make a decision regarding the next steps in the second half of 2010.

A survival registry following patients from the Company’s Phase III trial testing Oncophage in non-metastatic RCC has been closed. Final data collection is underway.

Data from a Phase 1 trial testing AG-707, a heat shock protein-based off-the-shelf therapeutic vaccine for the treatment of genital herpes has been analyzed. The findings are expected to be presented at a medical conference and/or published in a scientific/medical journal later this year.

AGEN’s partners, including GlaxoSmithKline, continue clinical development of approximately 15 vaccines containing AGEN’s’ QS-21 investigational adjuvant. Phase III programs include vaccines for malaria, melanoma and nonsmall cell lung cancer. AGEN would be entitled to receive milestone payments as these programs advance, as well as royalties for at least 10 years after commercial launch. The cost of developing and marketing these vaccines is assumed entirely by the company’s licensees. The first products containing QS-21 could be launch as early as the 2012/2013 timeframe.


Technical Analysis


AGEN is trading above its 50-day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.

AGEN is trading near its upper Bollinger Band. This suggests that the stock price is high relative to its recent price action.

AGEN’s MACD is indicating a weak bearish signal. Although the indicator is above the critical level of 0, which implies that the underlying moving averages are bullish, the MACD has crossed below its 9-day moving average or signal line. This suggests that positive momentum has begun to slow.

Comparative Analysis

Company Name Ticker Price per Mrkt. Cap. P/E P/S
May12-2010 symbol Share, $ $ Mn 2009 2010 2009 2010
Idera Pharmaceuticals Inc. IDRA 4.97 116.74M 15.74 n/a 3.90 n/a
Dynavax Technologies Corp. DVAX 1.81 98.39M n/a n/a 2.33 n/a
BioSante Pharmaceuticals Inc. BPAX 2.33 149.26M n/a n/a 109.98 n/a
Drug Manufacturers Median 121.46M n/a n/a 38.73 n/a
Antigenics Inc. AGEN 1.29 117.32M n/a n/a 26.18 n/a

Source: Thomson Financial

Insider Trading Activity


Inside Purchases – Last 6 Months

Shares Transaction
Purchases n/a 0
Sales 310,677 6
Net Shares Purchased (Sold) (310,677) 6
Total Insider Shares Held 19.41M n/a
% Net Shares Purchased (Sold) (1.6%) n/a

Net Institutional Purchases — Prior Qtr to Latest Qtr
Net Shares Purchased (Sold) (3,202,970)
% Change in Institutional Shares Held (33.9%)

Source: Yahoo Finance

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

Leave a Reply

Your email address will not be published. Required fields are marked *